How might Greenphire evolve its ConneX travel solution to better support global clinical trial participants?

Introduction

To evolve Greenphire's ConneX travel solution for better support of global clinical trial participants, we need to focus on enhancing the user experience, expanding global reach, and leveraging technology to streamline the travel process. I'll outline a strategic approach to improve this critical component of clinical trial management.

Step 1

Clarifying Questions (5 mins)

• Looking at the product context, I'm thinking ConneX might be at a critical growth stage where global expansion is key. Could you help me understand the current geographic coverage and which regions are priorities for expansion?

Why it matters: Determines if we focus on deepening existing markets or entering new ones. Expected answer: Currently strong in North America and Europe, looking to expand in Asia and South America. Impact on approach: Would prioritize features for language support, local transportation options, and regional compliance.

• Considering user behavior, I'm curious about the most common pain points participants face when using ConneX. What are the top 3 issues reported by users in the past six months?

Why it matters: Identifies immediate improvement areas that could significantly impact user satisfaction. Expected answer: Booking changes, reimbursement delays, and language barriers. Impact on approach: Would focus on developing flexible booking options, streamlining reimbursement processes, and enhancing language support.

• Regarding product lifecycle, I'm wondering about the current integration capabilities of ConneX. How well does it interface with other clinical trial management systems?

Why it matters: Determines if we need to focus on interoperability to improve overall trial efficiency. Expected answer: Basic integration exists, but there's room for improvement in real-time data sharing. Impact on approach: Would prioritize developing robust APIs and exploring partnerships with major CTMS providers.

• Considering external factors, I'm interested in understanding how recent global events, like the pandemic, have affected travel patterns for clinical trials. Have you seen a shift towards more localized or decentralized trial models?

Why it matters: Helps anticipate future needs and potential pivots in the product strategy. Expected answer: Increased demand for hybrid models combining remote and on-site visits. Impact on approach: Would focus on features supporting both traditional and decentralized trial models, such as local site selection and telemedicine integration.